Data / Drug companies / Rifamycin Antibacterial
Rifamycin Antibacterial drugs: 2 drugs from 15 companies in the FDA NDC directory
Rifamycin Antibacterial is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 23 products in this class from 15 companies, covering 2 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on July 20, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 15Companies
- 23Products
- 2Drugs by generic name
Drugs in the Rifamycin Antibacterial class
Ranked by number of companies that list the drug.
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 2 | capsule; tablet | Generic drugs (ANDA) | January 8, 2014 |
| American Health Packaging | 2 | capsule | Generic drugs (ANDA) | March 9, 2021 |
| Ani Pharmaceuticals, Inc. | 2 | capsule | Generic drugs (ANDA) | July 20, 2026 |
| Chartwell RX, LLC | 2 | capsule | Generic drugs (ANDA) | April 20, 2008 |
| Epic Pharma, LLC | 2 | capsule | Generic drugs (ANDA) | December 15, 2021 |
| Lupin Pharmaceuticals, Inc. | 2 | capsule | Generic drugs (ANDA) | January 8, 2014 |
| Puracap Laboratories LLC DBA Blu Pharmaceuticals | 2 | capsule | Generic drugs (ANDA) | March 14, 2023 |
| Salix Pharmaceuticals, Inc. | 2 | tablet | New drug applications (NDA) | May 1, 2010 |
| Bryant Ranch Prepack | 1 | capsule | Generic drugs (ANDA) | January 8, 2014 |
| Cardinal Health 107, LLC | 1 | tablet | New drug applications (NDA) | May 1, 2010 |
| Coupler LLC | 1 | capsule | Generic drugs (ANDA) | October 13, 2025 |
| Fresenius Kabi USA, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 21, 2014 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 3, 2016 |
| Major Pharmaceuticals | 1 | capsule | Generic drugs (ANDA) | February 25, 2025 |
| Mylan Institutional LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 21, 2015 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 16 | 69.6% |
| Tablet | 4 | 17.4% |
| Injection, powder, lyophilized, for solution | 3 | 13% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.